October 17, 2019 10:32 AM EDT
News Briefing

Af­ter 13% dis­count In­nate Phar­ma rais­es $69M; AZTher­a­pies bags $26.3M from Se­ries C fi­nanc­ing round

Kathy Wong

Editor

→ As­traZeneca-part­nered French biotech In­nate Phar­ma — which was shoot­ing for a $100 mil­lion IPO by of­fer­ing 10.7 mil­lions shares at $7.50 per share …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times